Formulary guidance and transparency from P&T to point of care


Reality Check on Hemophilia

Market access for hemophilia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Across all hemophilia A and B medications, 99% of Medicare beneficiaries are not covered for at least one of the drugs  
  • Class Trends: Starting Jan. 1, Express Scripts Holding Co. excluded Factor VIII recombinant products for hemophilia treatment in its 2019 National Preferred Formulary 
  • Key Findings: The market is trending toward longer half-life recombinant products

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.